X

Trial Profile

A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Tivozanib (Primary)
Indications Carcinoma; Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms TiNivo
Sponsors AVEO Oncology

Most Recent Events

02 Dec 2021 Status changed from active, no longer recruiting to completed.
09 Jul 2021 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.
05 Nov 2020 Results published in the AVEO Oncology Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com